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Abstract
Background: Conventional scale production of small batches of PET tracers (e.g. for
preclinical imaging) is an inefficient use of resources. Using O-(2-[18F]fluoroethyl)-L-
tyrosine ([18F]FET), we demonstrate that simple microvolume radiosynthesis techniques
can improve the efficiency of production by consuming tiny amounts of precursor, and
maintaining high molar activity of the tracers even with low starting activity.
Procedures: The synthesis was carried out in microvolume droplets manipulated on a
disposable patterned silicon “chip” affixed to a heater. A droplet of [18F]fluoride
containing TBAHCO3 was first deposited onto a chip and dried at 100 °C. Subsequently,
a droplet containing 60 nmol of precursor was added to the chip and the fluorination
reaction was performed at 90 °C for 5 min. Removal of protecting groups was
accomplished with a droplet of HCl heated at 90 °C for 3 min. Finally, the crude product
was collected in a methanol-water mixture, purified via analytical-scale radio-HPLC and
formulated in saline. As a demonstration, using [18F]FET produced on the chip, we
prepared aliquots with different molar activities to explore the impact on preclinical PET
imaging of tumor-bearing mice.
Results: The microdroplet synthesis exhibited an overall decay-corrected radiochemical
yield of 55 ± 7% (n = 4) after purification and formulation. When automated, the
synthesis could be completed in 35 min. Starting with < 370 MBq of activity, ~ 150
MBq of [18F]FET could be produced, sufficient for multiple in vivo experiments, with
high molar activities (48–119 GBq/μmol). The demonstration imaging study revealed the
uptake of [18F]FET in subcutaneous tumors, but no significant differences in tumor uptake
as a result of molar activity differences (ranging 0.37–48 GBq/μmol) were observed.
Conclusions: A microdroplet synthesis of [18F]FET was developed demonstrating low
reagent consumption, high yield, and high molar activity. The approach can be expanded
to tracers other than [18F]FET, and adapted to produce higher quantities of the tracer
sufficient for clinical PET imaging.
Keywords: Radiochemistry, Microfluidics, FET, Amino acid imaging, Droplet synthesis, Molar
activity, Pre-clinical imaging, Automation, Droplet microreactor
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Background
Positron emission tomography (PET) is a non-invasive molecular imaging tool based
on the use of positron-emitting isotopes to track the position and dynamics of biologic-
ally relevant molecules in the body. PET provides high-sensitivity quantitative
visualization of physiological parameters in vivo, such as metabolic rate, receptor dens-
ity, gene expression, or blood flow, which makes it a versatile and potent tool for clin-
ical diagnosis, treatment planning, treatment monitoring, as well as research (Aboagye
et al. 2001; Ambrosini et al. 2009; Ciernik et al. 2003; Kitson et al. 2009; Phelps 2000).
Safe preparation of various target-specific PET tracers is a complex and expensive
process, requiring skilled personnel operating expensive automated radiosynthesis
equipment within radiation-shielded “hot cells”. With conventional apparatus, in which
the chemistry is carried out in mL volume scales, relatively high reagent amounts (1 s
to 10s of mg) are needed to achieve a sufficient concentration for good reaction yield
in a short time, and for [18F]fluoride chemistry high amounts of radioactivity (10s of
GBq) are needed to achieve high molar activity (Sergeev et al. 2018a). These factors
contribute to inefficient use of resources in the preparation of small batches of tracers,
such as needed for preclinical imaging, or for a single clinical PET scan, where much of
the prepared batch would be wasted.
On the other hand, emerging microfluidic radiosynthesis methods require much
lower amounts of reagents and radionuclide, and through substantially reduced instru-
ment size and cost, have the potential to significantly reduce costs and resources
needed for radiopharmaceutical production. Microscale reactions also tend to be faster
and, due to the low precursor mass used, the crude products can be purified with sim-
pler methods (e.g. analytical-scale high-performance liquid chromatography (HPLC) or
cartridge instead of semi-preparative HPLC). These advantages are especially relevant
for smaller batch production of PET tracers, but can also benefit the production of lar-
ger batches (Chao et al. 2018b).
Of the several different microfluidic approaches reported in the last decade (Elizarov
2009; Keng and van Dam 2015; Miller et al. 2010; Pascali and Matesic 2016; Rensch et al.
2013), microvolume reaction approaches offer the greatest potential for reagent and in-
strument reductions (Dooraghi et al. 2013; Elizarov et al. 2010; Iwata et al. 2018; Keng
et al. 2016; Lebedev et al. 2012; Wang et al. 2017). A particular configuration we are ex-
ploring is performing reactions in microliter-sized droplets on simple Teflon-coated sili-
con microfluidic chips, which has advantages of simple operation, low-cost disposable
chips, and a compact system size, which reduces the necessary shielding. Previous work
has shown application of this method for the rapid and efficient synthesis of [18F]FDG
and [18F]Fallypride (Wang et al. 2017). In this paper, we demonstrate further versatility of
this approach by adapting the macroscale synthesis of O-(2-[18F]fluoroethyl)-L-tyrosine
([18F]FET) to this platform, and then use the produced [18F]FET for pre-clinical imaging.
[18F]FET is an amino acid PET probe (Wester et al. 1999), finding use in glioma im-
aging (Langen et al. 2017) as well as providing a route for protein labeling with
fluorine-18 (Yanai et al. 2019). The radiosynthesis of [18F]FET from the commercially
available precursor (2S)-O-(2′-tosyloxyethyl)-N-trityl-tyrosine-tert-butyl ester (TET)
consists of a radiofluorination step followed by a hydrolysis step. The conventional syn-
thesis typically results in good radiochemical yields (RCYs), ranging from 19 to 64%
(Bourdier et al. 2011; Bouvet et al. 2012; Hamacher and Coenen 2002; Iwata et al. 2018;
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Lakshminarayanan et al. 2016). Some efforts have been made to carry out the synthesis in
microfluidic format. Bouvet et al. performed the reaction in a commercial flow radio-
chemistry system using either microwave or heat activation of the reaction. An RCY of
50% was obtained with only 59 nmol of precursor in a 30 μL reaction in < 45min (Bouvet
et al. 2012), but to scale to larger production amounts (e.g., > 200MBq) would require
longer synthesis times and higher precursor amounts. Iwata et al. performed batch synthe-
sis in 10–20 μL volumes (180–350 nmol of precursor) within a small glass vial by first
loading a larger volume of methanolic solution containing [18F]fluoride and phase transfer
catalyst, evaporating the solvent, then adding the small volume of precursor solution and
performing the reaction (Iwata et al. 2018). Yields of up to 64 ± 11% (n = 3 ~ 6) were re-
ported at scales of < 400MBq. An automated procedure for this method was not de-
scribed and may be challenging in practice due to the difficulty of manipulating small
volumes in what is essentially a conventional apparatus.
We report a simple and rapid method for [18F]FET synthesis based on microvolume
droplet approach. The probe production with this method results in high RCY and high
molar activity using a very small amount of precursor and low starting activity. The
low precursor amount enables purification via analytical, rather than semi-preparative,
scale HPLC. This low-cost approach allowed us to carry out a large dynamic imaging
study of up to 8 mice within a single day, thus demonstrating that the method will be a
favorable option for pre-clinical studies of [18F]FET.
Materials and methods
Materials
Reagents and supplies
For the radiochemistry portion of this work, no-carrier-added [18F]fluoride was pro-
duced by the 18O(p, n)18F reaction from [18O]H2O (84% isotopic purity, Zevacor
Pharma, Noblesville, IN, USA) in an RDS-112 cyclotron (Siemens; Knoxville, TN, USA)
at 11MeV using a 1 mL tantalum target with havar foil. Acetonitrile (MeCN; anhyd-
rous, 99.8%), methanol (MeOH; anhydrous, 99.8%), ethanol (EtOH; 200 proof, > 99.5%),
hydrochloric acid (HCl; 1M), thexyl alcohol (2,3-dimethyl-2-butanol, 98%), trifluoroa-
cetic acid (TFA, 99%), deionized (DI) water, phosphate buffered saline (PBS; pH 7.4)
were purchased from Millipore Sigma (St. Louis, MO, USA). Saline (0.9% sodium
chloride injection, USP) was obtained from Hospira Inc. (Lake Forest, IL, USA). All re-
agents were used as received without further purification. 18MΩ water was obtained
from a purification system (RODI-C-12BL, Aqua solutions, Inc., Georgia, USA). Tetra-
butylammonium bicarbonate 0.075M (TBAHCO3, > 99%), (2S)-O-(2′-tosyloxyethyl)-
N-trityl-tyrosine-tert-butyl ester (TET, > 95%) precursor, O-2-fluoroethyl-L-tyrosine
standard (FET-HCl, > 95%) were purchased from ABX GmbH (Radeberg, Germany).
To perform uptake assays, GS025 and GBM39 cells were kindly provided by Dr. Da-
vid Nathanson (UCLA), the ParcB3 cells were provided by Dr. Peter Clark (UCLA), and
the HCT-15 and HCC827 cells were purchased from ATCC (Manassas, VA, USA).
Poly-L-lysine, protease inhibitor (cOmplete™), Hank’s balanced salt solution (HBSS;
10×), and fetal bovine serum (FBS),were purchased from Millipore Sigma (St. Louis,
MO, USA). 96 well plates, 96 well filter plates, 0.25% trypsin, 100× penicillin-
streptomycin (10,000 U/mL, Gibco™), RPMI-1640 medium (1×, Gibco™), GlutaMAX™ –
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I (100×, Life Technologies), Dulbecco’s Modified Eagle Medium (DMEM/F12), (100×),
epidermal growth factor recombinant human protein (EGF), fibroblast growth factor
recombinant human protein (FGF-Basic), heparin, and B27 supplement (50×) were pur-
chased from Thermo Fisher (Waltham, MA, USA).
Analytical methods
A calibrated ion chamber (CRC 25-PET, Capintec, Florham Park, NJ, USA) was used to
perform radioactivity measurements. For radio-thin-layer chromatography (TLC) ana-
lysis, TLC plates (Baker-flex silica gel IB-F sheets 2.5 × 7.5 cm, J.T. Baker, Phillipsburg,
NJ) were spotted with 1 μL samples of the crude intermediate, crude final product, or
purified final product, and were developed in 80% v/v MeCN in H2O, and then scanned
with a radio-TLC scanner (miniGita star, Raytest, Inc., Wilmington, NC, USA), or with
a Cerenkov luminescence imaging system (Dooraghi et al. 2013). Retention factors of
the observed radioactive species were: 0.0 ([18F]fluoride), 0.3 ([18F]FET), and 0.8 (fluori-
nated intermediate).
Radio-HPLC analysis and purification was performed on an analytical-scale Smartline
HPLC system (Knauer, Berlin, Germany) with 200 μL injection loop, a pump (Model
1000), degasser (Model 5050), a UV detector (Model 2500) and a radiometric detector
(Bioscan B-FC-4000, Bioscan Inc., Washington DC, USA). Samples were separated
using a C18 column (Luna, 4.6 × 250 mm, 5 μm, Phenomenex, Torrance, CA, USA)
with guard column (SecurityGuard C18, Phenomenex) at a flow rate of 1 mL/min. UV
absorbance was measured at 269 nm. Using 10% v/v EtOH in 18MΩ H2O mobile
phase, the expected retention time of [18F]fluoride was between 2 and 3min, and
around 5min for [18F]FET. The fluorinated intermediate was eluted off the column
using 100% MeCN.
Microfluidic systems
Radiochemistry was performed in droplet format on the surface of microfluidic chips
comprising a silicon wafer with a patterned Teflon AF coating. The detailed fabrication
was previously reported (Wang et al. 2017). A combination of hydrophobic (Teflon)
and hydrophilic (exposed silicon wafer) regions allows liquid droplets to be manipu-
lated or maintained in a desired location to perform reactions.
One type of chip, used for the synthesis optimization studies, had a 4 mm circular
hydrophilic region (i.e. Teflon coating etched away) serving as a reaction site (Fig. 1a).
During use, the chips were mounted to a temperature control platform comprising a
ceramic heater affixed to a Peltier device, which was in turn mounted on a heat sink
with a fan. A thin layer of thermal paste was present between all device components to
ensure good thermal contact. Reagents were loaded and product was collected manu-
ally via pipette with 10 or 200 μL tips.
Another type of chip, used for automated synthesis, had six radial tapered hydrophilic
pathways leading toward a central hydrophilic reaction site (Fig. 1b). The chip was
similarly mounted to a temperature-control platform, but reagents were added via elec-
tronically controlled piezoelectric actuators around the periphery of the chip and crude
product was collected by a retractable needle. The tapered pathways spontaneously
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transport reagent droplets from the periphery to the center of the chip. Complete de-
tails of this setup were reported previously (Wang et al. 2017).
Methods
Microscale radiosynthesis and purification of [18F]FET
The microscale synthesis was adapted from previously described macroscale protocols
(Bourdier et al. 2011; Hamacher and Coenen 2002) by scaling down reagent volumes
(Fig. 2). Cyclotron produced [18F]fluoride (37–740MBq in ~ 10–20 μL) was mixed with
110 nmol of TBAHCO3 (i.e., 1.5 μL of 75 mM solution), deposited on the chip and then
evaporated to dryness at 100 °C. After cooling to 30 °C, 10 μL of 6 mM TET (60 nmol)
in 1:1 v/v MeCN:thexyl alcohol was added to the chip. The reaction mixture was heated
at 90 °C for 5 min, and then cooled to 30 °C. Next, 20 μL of 1M HCl was added and the
deprotection reaction was performed by heating to 90 °C for 3 min. The crude product
was recovered by adding 20 μL of 1:1 v/v MeOH:H2O and collecting from the chip. The
collection process was repeated a total of 4 times to ensure high recovery of the crude
product. After synthesis, the product was diluted to 150–175 μL using HPLC mobile
phase (10% v/v EtOH in 18MΩ water) and purified via analytical-scale radio-HPLC.
The product peak was collected (typically 1.0–1.5 min duration) into a sterile glass vial.
Solvent was evaporated by heating the vial to 120 °C with an oil bath and applying a
Fig. 1 Side view schematic of manual a and automated b microvolume synthesis platform, and top view
photographs of corresponding chips used
Fig. 2 Synthesis scheme for microvolume production of [18F]FET using manual synthesis platform
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nitrogen stream above the surface of the solvent. When dry (typically after 10–15min),
the [18F]FET was then resuspended either in sterile saline for in vivo imaging, or pH 7.4
phosphate-buffered saline (PBS) for cell uptake experiments. Numerous intermediate
measurements were taken during synthesis to carefully analyze its performance (see de-
tails in Electronic supplementary material (ESM), Additional file 1: Sects. 1–2).
In vitro probe uptake
In vitro uptake of [18F]FET was compared across two glioblastoma cell lines (GS025,
GBM39), a prostate cancer cell line (ParcB3), a lung cancer cell line (HCC827), and a
colon cancer cell line (HCT-15). The GS025, GBM39, and ParcB3 suspension cells
were grown in stem cell media, and the HCC827 and HCT-15 adherent cells were
grown in supplemented RPMI. The suspension cells were plated into 96-well plates and
adherent cells into 96-well filter plates at 150, 000 cells/mL concentration in 1x HBSS.
[18F]FET was diluted to a concentration of 370 Bq/μL with either PBS (for uptake ex-
periments) or PBS containing 5 mM FET (for blocking experiments). Cell uptake exper-
iments were performed by adding 100 μL [18F]FET (37 kBq) to each of a set of cell
wells (n = 4), and blocking experiments (to confirm specificity) were performed by add-
ing 100 μL [18F]FET (37 kBq) with FET (500 nmol) to each of a set of cell wells (n = 4).
The cells were incubated at 37 °C for 10 min, then transferred into individual gamma
counter tubes and sample radioactivity was measured on a gamma counter (WIZARD
3″ 1480, Perkin Elmer, Waltham, MA, USA). The uptake values were normalized to
total protein amounts for each sample (complete details of the procedure are provided
in the ESM, Additional file 1: Sect. 3). The statistical significance of the values was vali-
dated by a two-tailed T test (p < 0.05).
In vivo preclinical imaging
Male NOD scid gamma (NSG) mice ~ 7 week-old were obtained from the UCLA De-
partment of Radiation Oncology. These mice (n = 10) were engrafted with 0.5 × 106
HCC827 cells suspended in a 1:1 (v/v) mixture of supplemented RPMI media and
Corning® Matrigel® Basement Membrane Matrix (Corning Life Sciences) in the left and
right shoulders.
To perform dynamic PET imaging, mice were kept under 2% isoflurane anesthesia
during the tracer uptake for 60 min. Mice were injected with 1.5–3.1 MBq of the tracer,
and were scanned 4 at a time using the recently developed HiPET scanner (Gu et al.
2017). The first study was performed with 4 mice injected with probe of different molar
activities in a range of 1.5–36 GBq/μmol (n = 1 each). The second study with 8 mice
covered molar activities ranging from 0.4–48 GBq/μmol (n = 2 each) (see Additional file
1: ESM, Sect. 4 for details). The concentration of FET in blood was estimated to range
between 0.02 and 3.5 μM assuming 2 mL average mouse blood volume. All mice re-
ceived 10 min CT scans (CrumpCAT (Taschereau et al. 2014)) following the PET im-
aging experiment. After PET/CT image registration, regions of interest (ROI) were
drawn with AMIDE version 1.0.5 software, and the results were analyzed by comparing
mean intensity values of the tumors and other regions across different time points (12
frames of 5 min each) (details on image analysis are described in ESM, Additional file
1: Sect. 5).
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Results
Microscale [18F]FET synthesis optimization and automation
To adapt the 2-step synthesis of [18F]FET from the macroscale to the microscale, the
precursor and base quantities were initially scaled down nearly 300–490-fold from
values reported in conventional synthesis (Bourdier et al. 2011; Hamacher and Coenen
2002), i.e. to 75 nmol of TBAHCO3 (1 μL, 0.075M) and 30 nmol of the TET precursor
in 20 μL. We used TBAHCO3 rather than K222/K2CO3 (Bourdier et al. 2011; Iwata
et al. 2018) based on the suggestion by Hamacher and Coenen (2002), who observed
higher yields due to the lower basicity and reduced competing elimination reaction.
One significant change we made was altering the fluorination reaction solvent. The
syntheses reported by Hamacher and Coenen (2002), Bourdier et al. (2011) and Laksh-
minarayanan et al. (2016) all used MeCN as the fluorination solvent, but in the droplet
format, we found that the MeCN evaporated very quickly, resulting in poor yields. After
exploring several solvent combinations that have been previously reported in droplet
reactions (Keng and van Dam 2015), a 1:1 v/v mixture of MeCN and thexyl alcohol was
selected. During early syntheses the fluorination temperature was set at 80 °C, slightly
lower than what has been reported in conventional syntheses (i.e., 85 °C (Hamacher
and Coenen 2002) or 100 °C (Bourdier et al. 2011)) to further mitigate evaporation, and
the reaction time was set for 5 min. Under these conditions, fluorination yield was 36 ±
7% (n = 4).
Investigation of the ratio of base to precursor (Fig. 3a) indicated that the originally
chosen ratio (~ 2.5) was close to optimal: a steep drop in fluorination efficiency was ob-
served for base to precursor ratios below 1.7 and higher than 2.5. When fluorinating
with 110 nmol of TBAHCO3 per 60 nmol of precursor (1.9 ratio) at 80 °C the fluorin-
ation yield reached 50 ± 1% (n = 4). Increasing the temperature to 90 °C further im-
proved the fluorination yield to 63 ± 3% (n = 4) (Fig. 4). Lower reaction temperature
(75 °C) resulted in similar yield as the 80 °C reaction, though solvent evaporation was
slightly reduced (Fig. 4). Later, the reaction volume was reduced to 10 μL keeping the
same amount (60 nmol) of precursor per reaction to make it more compatible with
chip chemistry, however no significant change in reaction yield was observed.
For the deprotection step, we initially attempted to use TFA as reported by Hama-
cher and Coenen (2002) and Bouvet et al. (2012); however, we observed rapid
Fig. 3 a Effect of base to precursor ratio on fluorination efficiency and fluorination yield (n = 1 for each data
point). Syntheses carried out at 80 °C for 5min with 30 nmol or 60 nmol of precursor. b Effect of deprotectant
(10 μL HCl) concentration on deprotection reaction at 90 °C for 3 min (n = 1 for each condition). Synthesis
performed with 60 nmol precursor and 110 nmol TBAHCO3 at 90 °C for 5min
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evaporation of TFA and low deprotection efficiency. We then explored the use of HCl,
as reported by Bourdier et al. (2011) and Lakshminarayanan et al. (2016). Using a
deprotection reagent volume of 10 μL heated for 3 min at 90 °C, we explored the effect
of different HCl concentrations (Fig. 3b). Higher concentrations resulted in more
complete deprotection of the intermediate. The use of 10 μL of 1.0M HCl was suffi-
cient to deprotect most of the intermediate (~ 94%). Increasing the volume from 10 to
20 μL led to improved hydrolysis and was used in all subsequent experiments. Conveni-
ently, the acid nearly fully evaporates during the hydrolysis step leaving only trace
amounts of liquid, obviating the need for neutralization.
The manual synthesis of the crude product, under optimized conditions, required
24 ± 2min (n = 4). The collection efficiency was 64 ± 5% (n = 4) and radiochemical con-
version of [18F]FET was 92 ± 4% (n = 4) resulting in crude RCY of 59 ± 7% (n = 4).
Fluorination yield was estimated to be 62 ± 8% (n = 4), and hydrolysis efficiency was
96 ± 2% (n = 4). Only 1.3 ± 0.5% (n = 4) of the starting activity was attributed to residual
activity on the chip after collection of the crude product, though an additional loss of
35 ± 6% (n = 4) was observed, potentially corresponding to loss of unreacted [18F]fluor-
ide in the form of [18F]HF during the acidic deprotection step.
Production of [18F]FET for imaging was performed using this manual protocol,
followed by purification by analytical HPLC (~ 5min) and formulation (10–15min),
resulting in an overall synthesis time of 40 min. The loss during purification and formu-
lation was 7 ± 3% (n = 4) and overall decay corrected RCY was 55 ± 7% (n = 4). The
identity of the purified product was confirmed via analytical radio-HPLC by co-
injection with the reference standard. Radiochemical purity of the final product as de-
termined via radio-HPLC was > 98%. Molar activity was 48–119 GBq/μmol at the end
of synthesis.
We also performed the synthesis using the automated droplet radiosynthesizer
(i.e. with the passive transport microfluidic chips) and observed a crude decay-
corrected RCY of 54 ± 6% (n = 5) (a detailed comparison of the performance of the
manual and automated droplet synthesis processes is summarized in Table 1). In
general, the performance was very similar, the main difference being slightly lower
collection efficiency with the automated procedure. An advantage of the automated
synthesis is that the synthesis of the crude product was completed in a shorter
time (5 min less).
Fig. 4 Results of initial optimization of fluorination conditions. Error bars represent standard deviations (n = 4)
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In vivo imaging at varying molar activities of [18F]FET
As a demonstration of the ability to perform a preclinical imaging study with [18F]FET
produced using the microscale method, we prepared [18F]FET of different molar activ-
ities to investigate the impact on in vivo imaging. It has been previously seen with im-
aging of [18F]Fallypride that molar activity can significantly affect the PET imaging
contrast in the striata of the brain (Sergeev et al. 2018b), whereas variations in molar
activity of [18F]FDOPA were reported not to impact the imaging of neuroendocrine tu-
mors (Kuik et al. 2015). [18F]FET is one of the major fluorine-18 labeled amino acids
used in glioma imaging, grading and therapy planning. [18F]FET is an L-tyrosine
analogue, and it helps to visualize amino acid transport activity that is upregulated in
many growing tumors (Langen et al. 2006, 2017).
To perform experiments, samples with different molar activities were prepared from
a single batch of [18F]FET. The batch was divided into four aliquots, then each aliquot
was spiked with different amounts of the reference standard and saline to achieve dif-
ferent molar activity values with the same radioactivity concentration (details of the
preparation are included in the ESM, Additional file 1: Sect. 4).
The cell uptake comparison among few different cell lines had shown that the lung
cancer cell line HCC827 had a significantly higher probe uptake than any of the other
cell lines tested (GS025, GBM39, ParcB3, HCT-15) (Fig. 5) and was used for in vivo
study. Subcutaneous tumor HCC827 xenograft models had reached sufficient tumor
size for imaging (~ 4mm diameter) after 36 days when an initial imaging experiment
was performed (ESM, Additional file 1: Fig. S3), followed by another study at 50 days
post-implantation (ESM, Additional file 1: Fig. S4). Dynamic PET/CT scans were per-
formed with injections of different molar activities. In all cases, the signal in the blood
was high after injection and decreased over time. Muscle and tumor uptake rose grad-
ually and plateaued at ~ 30 min, remaining nearly constant until the end of the scan.
No bone uptake was observed in scans, confirming the lack of in vivo defluorination.
Combined dynamic imaging data is summarized in ESM, Additional file 1: Fig. S5–7.
The tumor to blood ratio increased during the first 15–20 min and then remained
nearly constant for the rest of the scan, while the tumor to muscle ratio remained
nearly constant throughout the scan (Additional file 1: Fig. S7). Qualitatively, it is ap-
parent there is no strong correlation between the tumor uptake ratios and the molar
activity values. Tumors imaged at low molar activity were as easily visible as tumors
Table 1 Summary of performance of microdroplet synthesis of [18F]FET with optimized manual
operation or automated operation. All values are decay-corrected unless otherwise specified
Manual (n = 4) Automated (n = 5)
Collection efficiency (%) 64 ± 5 59 ± 10
Residual chip activity (%) 1.3 ± 0.5 3 ± 1
Volatile activity loss (%) 35 ± 6 38 ± 11
Fluorination yield (%) 62 ± 8 59 ± 10
Radiochemical conversion to FET (%) 92 ± 4 93 ± 6
Deprotection efficiency (%) 96 ± 2 93 ± 6
Crude RCY (%) 59 ± 7 54 ± 6
Crude synthesis time (min) 24 ± 2 19 ± 2
Crude RCY, non-decay-corrected (%) 51 ± 6 48 ± 5
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imaged at high molar activity of the injected probe. The uptake ratios averaged during
the final 30–60 min of the scans summarized for different molar activity values did not
exhibit any correlation either (Fig. 6). The statistically insignificant correlation between
uptake ratios and molar activity was confirmed using a Spearman correlation test (rs =
− 0.3 for tumor to muscle ratio, rs = 0.1 for tumor to blood ratio).
Discussion
Microscale synthesis
The microscale synthesis described here was performed quickly, reliably and in high
yield, allowing production of the tracer for pre-clinical studies. A comparison of the
performance of the microvolume synthesis compared to conventional synthesis is in-
cluded in Table 2. The consumption of reagents was reduced drastically (> 150 × less
precursor) compared to conventional methods, while still achieving comparable RCY.
Though optimization runs (requiring numerous intermediate measurements), and
batches for imaging (where molar activity adjustments were needed at the end) took
longer to prepare, the fully-automated microvolume synthesis can be completed in 35
Fig. 5 Accumulation of [18F]FET in different cell lines. Error bars represent standard deviation (n = 4). (*) p <
0.05, (**) p < 0.01, (***) p < 0.001. The red bars indicate incubation with both [18F]FET and 2.5 mM FET
reference standard to establish specificity
Fig. 6 Tumor to muscle and tumor to blood ratios averaged for all tumors within the same molar activity
value group (n = 4 except as otherwise indicated) and averaged over the dynamic imaging data from 30 to
60min. Error bars represent standard deviation
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min (19 min synthesis + 6 min purification via analytical-HPLC + 10min formulation).
This is significantly faster than macroscale synthesis methods, and is a significant ad-
vantage when considering non-decay-corrected RCY. The short synthesis time origi-
nates from the smaller reaction volume, which enables faster temperature change and
shorter solvent removal times, as well as from the low precursor mass, which enables
the use of analytical scale HPLC purification rather than semi-preparative. Interestingly,
the droplet method also resulted in shorter synthesis time and higher yield compared
to recent reports of [18F]FET synthesis in smaller volumes (10s of microliters) using
manual liquid manipulation or flow-through reactors (Table 2).
Under optimized conditions, a batch of [18F]FET suitable for preclinical imaging
throughout the day (e.g. 37–110MBq; assuming 0.93–7.4MBq per injection for 5–10
mice) could be produced on the microscale platform starting with only 110–330MBq
of [18F]fluoride. Limiting the activity to relatively low levels in this manner could have
significant advantages for shielding the apparatus (i.e., thinner shielding would be ad-
equate) and possibly operating the synthesis outside of a hot cell.
The droplet synthesis (even with starting activities lower than 0.74 GBq) resulted in
high molar activities, comparable to the values achieved on macroscale synthesizers
starting with > 30 GBq of fluoride-18. It should be appreciated that, when the starting
activity is scaled down in macroscale radiosynthesizers, one observes a linear decrease
in the resulting molar activity (Sergeev et al. 2018a). Thus, high amounts of starting ac-
tivity must often be used in macroscale synthesizers, even if only a relatively small
amount of the final tracer is needed. Compared to microscale synthesis, this can result
in higher cost of the radioisotope, and the need for considerably more shielding to
work with the higher activity levels.
Overall, the microvolume synthesis of radiopharmaceuticals has a number of advan-
tages over conventional scale radiosynthesizers such as more compact apparatus, re-
duced shielding, rapid synthesis, high yield, and efficient use of radioisotope. These
advantages have the potential to drive down the costs of materials and infrastructure,
which can be a significant benefit for limited resource settings or preclinical tracer pro-
duction. Another advantage – low precursor consumption – not only helps to simplify
the purification step, but can also represent a significant cost reduction, especially for
tracers with expensive precursors, or in situations where precursor is scarce, such as
the development of novel tracers or optimization of synthesis protocols. While the
strengths of this technology are in reducing costs of small batches of tracers, e.g. to
support in vitro or preclinical studies, various microfluidic technologies are constantly
improving and expanding their applications in the radiopharmacy field, and could also
lead to improvements in the efficiency of clinical PET tracer production in the future
(Pascali et al. 2013), such as enabling the production of additional tracers with minimal
need for extra space or capital.
[18F]FET imaging
Over the range tested (0.37–48 GBq/μmol), the molar activity had no statistically sig-
nificant effect on imaging of subcutaneous HCC827 tumors. [18F]FET accumulates in
cells following transport by Na+-dependent and -independent amino acid transporters
and is not incorporated into proteins over the time course of the imaging experiments
Lisova et al. EJNMMI Radiopharmacy and Chemistry             (2020) 5:1 Page 11 of 15
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(Heiss et al. 1999; Langen et al. 2003). The results suggest that the [18F]FET trans-
porters on the lung cancer cell line HCC827 do not become saturated within the range
of molar activity values tested. Though the in vitro experiments suggest that the trans-
porters can be “saturated” with sufficient concentration of FET in the media (i.e., 2.5
mM in the case “spiked” with FET; 0.15 μM in the non-spiked condition), the estimated
concentration of FET in blood during the in vivo experiments was much lower (i.e.
3.5 μM for the lowest molar activity of 0.37 GBq/μmol, assuming 2 mL blood volume).
Conclusion
In this work the synthesis of [18F]FET was adapted to an automated microdroplet syn-
thesis platform (Wang et al. 2017). The product was obtained in high RCY of up to
55 ± 7% (n = 4, decay-corrected) after purification, in sufficient quantities to perform a
demonstration of a multi-animal dynamic PET imaging study, and could readily be
scaled to higher amounts using radionuclide concentration methods (Chao et al.
2018a). Synthesis time was shorter than conventional approaches, precursor consump-
tion was reduced by two orders of magnitude, and the synthesis could be performed
with a very small apparatus. The low precursor consumption enabled faster and simpler
purification (i.e., analytical HPLC instead of semi-preparative HPLC), and, for tracers
with expensive precursors, could help to reduce the synthesis cost. The molar activity
was high (48–119 GBq/μmol at the end of synthesis), even when starting with activities
as low as 0.3 GBq. Though low molar activity of [18F]FET, (down to 0.37 GBq/μmol)
did not appear to adversely affect imaging of subcutaneous tumors in this study, the
ability to produce small batches with high molar activity may be important in other ap-
plications of this or other tracers.
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